Chalkou, Konstantina; Vickers, Andrew J; Pellegrini, Fabio; Manca, Andrea; Salanti, Georgia (2023). Decision Curve Analysis for Personalized Treatment Choice between Multiple Options. Medical decision making, 43(3), pp. 337-349. Sage Publications 10.1177/0272989X221143058
|
Text
Chalkou_MedDecisMaking_2023.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (1MB) | Preview |
BACKGROUND
Decision curve analysis can be used to determine whether a personalized model for treatment benefit would lead to better clinical decisions. Decision curve analysis methods have been described to estimate treatment benefit using data from a single randomized controlled trial.
OBJECTIVES
Our main objective is to extend the decision curve analysis methodology to the scenario in which several treatment options exist and evidence about their effects comes from a set of trials, synthesized using network meta-analysis (NMA).
METHODS
We describe the steps needed to estimate the net benefit of a prediction model using evidence from studies synthesized in an NMA. We show how to compare personalized versus one-size-fit-all treatment decision-making strategies, such as "treat none" or "treat all patients with a specific treatment" strategies. First, threshold values for each included treatment need to be defined (i.e., the minimum risk difference compared with control that renders a treatment worth taking). The net benefit per strategy can then be plotted for a plausible range of threshold values to reveal the most clinically useful strategy. We applied our methodology to an NMA prediction model for relapsing-remitting multiple sclerosis, which can be used to choose between natalizumab, dimethyl fumarate, glatiramer acetate, and placebo.
RESULTS
We illustrated the extended decision curve analysis methodology using several threshold value combinations for each available treatment. For the examined threshold values, the "treat patients according to the prediction model" strategy performs either better than or close to the one-size-fit-all treatment strategies. However, even small differences may be important in clinical decision making. As the advantage of the personalized model was not consistent across all thresholds, improving the existing model (by including, for example, predictors that will increase discrimination) is needed before advocating its clinical usefulness.
CONCLUSIONS
This novel extension of decision curve analysis can be applied to NMA-based prediction models to evaluate their use to aid treatment decision making.
HIGHLIGHTS
Decision curve analysis is extended into a (network) meta-analysis framework.Personalized models predicting treatment benefit are evaluated when several treatment options are available and evidence about their effects comes from a set of trials.Detailed steps to compare personalized versus one-size-fit-all treatment decision-making strategies are outlined.This extension of decision curve analysis can be applied to (network) meta-analysis-based prediction models to evaluate their use to aid treatment decision making.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM) |
Graduate School: |
Graduate School for Health Sciences (GHS) |
UniBE Contributor: |
Chalkou, Konstantina, Salanti, Georgia |
Subjects: |
600 Technology > 610 Medicine & health 300 Social sciences, sociology & anthropology > 360 Social problems & social services |
ISSN: |
0272-989X |
Publisher: |
Sage Publications |
Funders: |
[222] Horizon 2020 |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
19 Dec 2022 11:22 |
Last Modified: |
22 Mar 2023 15:47 |
Publisher DOI: |
10.1177/0272989X221143058 |
PubMed ID: |
36511470 |
Uncontrolled Keywords: |
clinical usefulness decision curve analysis net benefit network meta-analysis prediction model |
BORIS DOI: |
10.48350/175941 |
URI: |
https://boris.unibe.ch/id/eprint/175941 |